A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
OBJECTIVE: This post hoc analysis of SURMOUNT trials assessed the association of baseline physical function (PF) with obesity-related complications (ORCs), efficacy measures, and PF. The mechanism of tirzepatide-led improvements in PF was evaluated.…
BACKGROUND: Diabetes mellitus, a global epidemic, necessitates robust evidence synthesis to guide clinical practice. This study analyzes systematic reviews and meta-analyses in diabetes research to identify trends, gaps, and key insights for advancin…
In real-world settings, the incidence of diabetes remission remains low. The factors identified as being associated with diabetes remission included a short duration of diabetes, low baseline hemoglobin A1c (HbA1c) levels, absence of ongoing diabetes…
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for weight management. Although generally well-tolerated, these agents may alter the pharmacokinetics of concurrently administered medications. CASE PRESE…
OBJECTIVES: To assess longterm weight and comorbidity outcomes following bariatric surgery at a publicly funded obesity service. DESIGN: Retrospective cohort study. SETTING AND PARTICIPANTS: Cohort of 203 individuals who underwent bariatric surgery b…
Tirzepatide is a dual gastric inhibitory polypeptide and glucagon-like peptide-1 receptor agonist, used for the treatment of type 2 diabetes mellitus and obesity. While gastrointestinal side effects are well described in the literature, hepatotoxicit…
Glucagon-like peptide-1 (GLP-1)-based medications, such as semaglutide and tirzepatide, have transformed obesity care. However, rising use brings concerns about side effects, long-term outcomes, and unregulated products. Ensuring safe access requires…
OBJECTIVE: To examine whether initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with seizure recurrence and related outcomes in adults with epilepsy and type 2 diabetes. METHODS: We conducted a retrospective cohort stu…
Tirzepatide is a synthetic polypeptide classified as glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist. It stimulates insulin secretion from the pancreas and helps lower blood sugar levels in patients with type 2 d…
BACKGROUND: Obesity-related heart failure with preserved ejection fraction (HFpEF) is associated with high morbidity and limited therapeutic options. Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like…
Obesity, diabetes, and menopause impair hypothalamic regulation of energy balance by inducing inflammation, cellular stress, and disruption of neuropeptide signaling. In a female mouse model combining these conditions, we investigated whether tirzepa…
BACKGROUND: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has demonstrated significant efficacy in weight reduction and glycemic control in patients with type 2 diabete…
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for weight management and cardiometabolic health. Common peroneal neuropathy (CPN) associated with rapid weight loss is attributed to adipose tissue reduction and subsequent n…
PURPOSE OF REVIEW: Obstetricians and gynecologists increasingly encounter patients using glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide agonists. This review synthesizes evidence on these…
A man in his 50s with insulin-treated type 2 diabetes mellitus presented with a 1-day history of severe abdominal pain, nausea and vomiting, 15 days after initiation of tirzepatide. On admission, he was severely dehydrated with profound high-anion ga…
Recent retrospective cohort studies showed that use of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) increased the incident risk of diabetic retinopathy and nonarteritic anterior ischemic optic neuropathy (NAION). Furthermore, it was r…
Obesity and its sequelae cause significant morbidity and mortality worldwide. Current glucagon-like peptide-1 (GLP-1) receptor agonist-based treatments have significant side-effects associated with high rates of treatment discontinuation. Such concer…
INTRODUCTION: obesity is a chronic and relapsing disease. Tirzepatide, a dual GLP-1 and GIP receptor agonist, has demonstrated weight loss exceeding 20 % at higher doses. However, real-world data remain limited, particularly regarding body compositio…